Skip to main content
SpringerLink
Log in

Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs

  • Immunosuppression and Inflammations
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Interleukin-1 (IL-1) activity and the acute phase response, as measured by plasma CRP and iron, were used to determine if the standard disease modifying antirheumatic drugs (DMARDs), gold, chloroquine andd-penicillamine had a common profile of activity in the adjuvant arthritic (AA) rat. All drugs were tested at a dose which significantly reduced noninjected paw swelling in AA rats. Inhibition of paw edema ranged from 37% ford-penicillamine (100 mg/kg) to 69% for auranofin (10 mg/kg). Two week medication of AA rats with gold sodium thiomalate (GST, 10 mg/kg, i.m.) or auranofin (10 mg/kg, p.o.) resulted in a significant decrease in splenic IL-1 activity, as measured in the standard lymphocyte activating factor (LAF) assay. The acute phase response, often associated with elevated IL-1 activity, was also significantly reduced following treatment of AA rats with 10 mg/kg of GST or auranofin (oral gold). Inhibition of the acute phase response by gold was determined by a significant reduction of plasma CRP levels (56–71% reduction) and enhancement of plasma iron levels (27–52% enhancement).

In contrast to the effect of GST and auranofin on IL-1, CRP and iron, treatment with chloroquine (20, 30 and 35 mg/kg) andd-penicillamine (55 and 100 mg/kg) failed to reduce the acute phase response (as measured by plasma CRP and iron) or alter LAF activity from AA rat spleen cell supernatants. Based on its ability to reduce LAF activity in spleen cell supernatants and reduce the acute phase response, it is possible that the activity of gold in the AA rat may in part be due to its ability to inhibit IL-1 productionin vivo. The inability of chloroquine andd-penicillamine to alter LAF activity and the acute phase response in AA rats does not preclude their possession of an immunoregulatory mechanism of action, but it does indicate that their mechanism of action in the AA rat probably differs from that of GST and auranofin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. A. Fontanta, H. Hengartner, E. Weber, K. Fehr, P. J. Grob and G. Cohen,Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol. Int.2, 49–53 (1982).

    Article  PubMed  Google Scholar 

  2. P. Tan, A. Shore, P. Leary, and E. C. Keystone,Interleukin abnormalities in recently active rheumatoid arthritis. J. Rheumatol11, 593–596 (1984).

    PubMed  Google Scholar 

  3. R. A. D. Bunning, H. J. Richardson, A. Crawford, H. Skjodt, D. Hughes, D. B. Evans, M. Gowen, P. R. M. Dobson, B. L. Brown and R. G. G. Russell,The effect of Interleukin-1 on connective tissue metabolism and its relevance to arthritis. Agents Actions Suppl.18, 131–152 (1986).

    Google Scholar 

  4. C. A. Dinarello,Interleukin-1. Rev. Infect. Dis.6, 51–95 (1984).

    PubMed  Google Scholar 

  5. K. D. Scott, J. A. Schmidt and J. J. Oppenheim,Interleukin-1: An immunological perspective. Ann. Rev. Immunol.3, 263–287 (1985).

    Article  Google Scholar 

  6. C. A. Dinarello,Interleukin-1 and the pathogenesis of the acute-phase response. N. Engl. J. Med.311, 1413–1418 (1984).

    PubMed  Google Scholar 

  7. K. Bendtzen, J. Peterson, J. Halkjaer-Kristensen and T. Ingemann-Hansen,Interleukin-1 like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis. Rheumatol. Int.5, 79–82 (1985).

    Article  PubMed  Google Scholar 

  8. R. K. Mallya, D. Vergani, D. E. H. Tee, L. Bevis, F. C. deBeer, H. Berry, E. D. Hamilton, B. E. Mace and M. B. Pepys,Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin. Exp. Immunol.48, 747–753 (1982).

    PubMed  Google Scholar 

  9. A. G. Mowat,Hematologic abnormalities in rheumatoid arthritis. Semin. Arthritis. Rheum.1, 195–211 (1971).

    Article  Google Scholar 

  10. A. J. Lewis and D. T. Walz,Immunopharmacology of gold. Progress in Med. Chem.19, 1–58 (1982).

    Google Scholar 

  11. A. L. Scherbel,Use of synthetic antimalarial drugs and other agents for rheumatoid arthritis. Historic and therapeutic perspectives. Am. J. Med.75 (IA), 1–4 (1983).

    Article  Google Scholar 

  12. Multicentre Trial Group,Controlled trial of d-penicillamine in severe rheumatoid arthritis. Lancet1, 275–280 (1973).

    Google Scholar 

  13. M. J. DiMartino and D. T. Walz,Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. Inflammation2, 131–142 (1977).

    Article  PubMed  Google Scholar 

  14. M. Harth,Gold and modulation of the immune response. J. Rheumatol.6 (Suppl. 5), 7–11 (1979).

    PubMed  Google Scholar 

  15. R. J. Ward, P. Doshi, G. Cashmore, A. Howard, P. J. Prouse and J. M. Gumpel,Clinical significance of trace metal alterations in patients receiving either Myocricin or auranofin. InInternational Symposium on Auranofin (Ed. Chappel) pp. 389–397, Excerpta Medica Amsterdam 1983.

    Google Scholar 

  16. V. J. Stecher, J. A. Carlson, K. M. Connolly and D. M. Bailey,Disease-modifying antirheumatic drugs. Med. Res. Rev.5, 371–390 (1985).

    PubMed  Google Scholar 

  17. T. W. Bunch and J. D. O'Duffy,Disease-modifying drugs for progressive rheumatoid arthritis. Mayo Clin. Proc.55, 161–179 (1980).

    PubMed  Google Scholar 

  18. P. E. Lipsky,Disease-modifying drugs. InArthritis, Etiology, Diagnosis, Management (Eds. P. D. Utsinger, N. J. Zvaifler and G. E. Ehrlich) pp. 601–634, J. B. Lippincott, Philadelphia 1985.

    Google Scholar 

  19. M. A. Scheinberg, L. Santos and A. Finkelstein,Gold inhibition of human monocyte function. Arthritis Rheum.24, S117 (1981).

    Google Scholar 

  20. D. A. Norris, W. L. Weston and W. M. Sams,The effect of immunosupressive and anti-inflammatory drugs on monocyte function in vitro. J. Lab. Clin. Med.90, 569–580 (1977).

    PubMed  Google Scholar 

  21. P. Davis, C. L. Miller and A. S. Russell,Effects of gold compounds on the respiratory burst of phagocytic cells. Arthritis Rheum.25, S131 (1982).

    Google Scholar 

  22. P. E. Lipsky and M. Ziff,Inhibition of antigen and mitogen induced human lymphocyte proliferation by gold compounds. J. Clin. Invest.59, 455–466 (1977).

    PubMed  Google Scholar 

  23. G. Salmeron and P. E. Lipsky,Immunosuppressive potential of antimalarials. Amer. J. Med.75, Suppl. 1A, 19–24 (1983).

    Article  Google Scholar 

  24. L. Binderup, E. Bramm and E. Arrigoni-Martelli,d-penicillamine and macrophages: Modulation of lymphocyte transformation by concanavalin. A. Scand. J. Immunol.7, 259–264 (1978).

    Google Scholar 

  25. P. Lipsky,Mechanisms of action of d-penicillamine in rheumatoid arthritis. Adv. in Inflammation Res.7, 175–183 (1983).

    Google Scholar 

  26. M. E. J. Billingham,Models of arthritis and the search for anti-arthritic drugs. Pharmac. Ther.21, 389–428 (1983).

    Article  Google Scholar 

  27. W. J. Johnson, K. A. Muirhead, P. C. Meunier, B. J. Votta, J. C. Schmitt, M. J. DiMartino and N. Hanna,Macrophage activation in rat models of inflammation and arthritis. Arthritis Rheum.29, 1122–1130 (1986).

    PubMed  Google Scholar 

  28. W. J. Johnson, M. J. DiMartino and N. Hanna,Macrophage activation in rat models of inflammation and arthritis. Determination of markers of stages of activation. Cell. Immunol.103, 54–64 (1986).

    Article  PubMed  Google Scholar 

  29. K. M. Connolly, V. J. Stecher, E. Danis, D. J. Pruden and T. LaBrie,Alteration of Interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. Inter. J. Immunopharmacol. (in press).

  30. M. J. DiMartino, J. C. Lee, A. M. Badger, K. A. Muirhead, C. K. Mirabelli and N. Hanna,Antiarthritic and immunoregulatory activity of spirogermanium. J. Pharmacol. Exp. Ther.236, 103–110 (1986).

    PubMed  Google Scholar 

  31. M. J. DiMartino, W. J. Johnson, B. Votta and N. Hanna,Effect of antiarthritic drugs on the enhanced Interleukin-1 production by macrophages from adjuvant-induced arthritic rats. Agents Actions21, 348–350 (1987).

    Article  PubMed  Google Scholar 

  32. S. C. Gilman, J. F. Daniels, R. E. Wilson, R. P. Carlson and A. J. Lewis,Lymphoid abnormalities in rats with adjuvant-induced arthritis. 1. Mitogen responsiveness and lymphokine synthesis. Ann. Rheum. Dis.43, 847–855 (1984).

    PubMed  Google Scholar 

  33. N. M. Young and R. E. Williams,Comparison of the secondary structures of binding sites of C-reactive protein and the phosphorylcholine-binding murine myeloma proteins. J. Immunol.121, 1893–1898 (1978).

    PubMed  Google Scholar 

  34. A. Nagpurkar and S. Mookerjea,A novel phosphorylcholine-binding protein from rat serum and its effect on heparinlipoprotein complex formation in the presence of calcium. J. Biol. Chem.256, 7440–7448 (1981).

    PubMed  Google Scholar 

  35. M. Pontet, M. D'Asnieres, D. Gache, J. Escaig and R. Engler,A new pentraxin (serum amyloid p-component) in the rat. Evidence for two quaternary structures and effect of ligands on self-association. Biochemica et Biophysica Acta671, 202–210 (1981).

    Google Scholar 

  36. F. C. deBeer, M. L. Baltz, E. A. Munn, A. Feinstein, J. Taylor, C. Bruton, J. R. Clamp and A. M. Pepys,Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology45, 55–70 (1982).

    PubMed  Google Scholar 

  37. K. Connolly, V. J. Stecher, J. K. Saelens and J. E. Kaplan,The relationship between plasma fibronectin levels and autoimmune disease activity in MRL/1 mice. Proc. Soc. Exp. Biol. Med.180, 149–154 (1985).

    PubMed  Google Scholar 

  38. C. B. Laurell,Electroimmunoassay. Scand. J. Clin. Lab. Invest. (Suppl. 124)29, 21–37 (1972).

    Google Scholar 

  39. M. J. DiMartino, J. C. Lee, B. Votta and N. Hanna,Effect of antiarthritic drugs on aberrant interleukin production in adjuvant arthritic rats. Arthritis Rheum.29, S99 (1986).

    Google Scholar 

  40. A. Anderson,Lysosomal enzyme activity in rats with adjuvant-induced arthritis. Ann Rheum. Dis.29, 307–313 (1970).

    PubMed  Google Scholar 

  41. D. E. Griswold, J. C. Lee and N. Hanna,Immunoregulatory activity of auranofin, modulation of antigen presentation, Interleukin production and suppressor T-cell induction. Arthritis Rheum27, S58 (1984).

    PubMed  Google Scholar 

  42. J. C. Lee, M. J. DiMartino, B. J. Votta and N. Hanna,Effect of auranofin treatment on aberrant splenic Interleukin production in adjuvant arthritic rats. J. Immunol.139, 3268–3274 (1987).

    PubMed  Google Scholar 

  43. E. D. Harris,Pathogenesis of rheumatoid arthritis and the development of rational drug therapy. J. Rheumatol. (Suppl. 8)9, 3–9 (1982).

    PubMed  Google Scholar 

  44. C. A. Dinarello, J. G. Cannon, S. M. Wolff, H. A. Bernheim, B. Beutler, A. Cerami, I. S. Figari, M. A. Palladino and J. V. O'Connor,Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of Interleukin-1. J. Exp. Med.163, 1433–1450 (1986).

    Article  PubMed  Google Scholar 

  45. M. E. J. Billingham,Cytokines as inflammatory mediators. Br. Med. Bul.47, 350–370 (1987).

    Google Scholar 

  46. D. G. Ritchie and G. M. Fuller,Hepatocyte-stimulating factor: a monocyte-derived acute-phase regulatory protein. New York Acad. Sci.408, 490–500 (1983).

    Google Scholar 

  47. H. Baumann, G. P. Jahreis, D. N. Sauder and A. Koj,Human keratinocytes and monocytes release factors which regulate the synthesis of major acute phase plasma proteins in hepatic cells from man, rat and mouse. J. Biol. Chem.259, 7331–7342 (1984).

    PubMed  Google Scholar 

  48. D. C. Hooper, C. J. Steer, C. A. Dinarello and A. C. Peacock.Haptoglobin and albumin synthesis in isolated rat hepatocytes. Biochimica et Biophysica Acta653, 118–129 (1981).

    PubMed  Google Scholar 

  49. M. S. Klempner, C. A. Dinarello and J. I. Gallin,Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J. Clin. Invest.61, 1330–1336 (1978).

    PubMed  Google Scholar 

  50. J. L. Van Snick, P. L. Masson and J. F. Heremans,The involvement of latoferrin in the hyposideremia of acute inflammation. J. Exp. Med.140, 1068–1084 (1974).

    Article  PubMed  Google Scholar 

  51. J. S. Dixon, H. A. Bird, N. G. Sitton, M. E. Pickup and V. Wright,C-reactivated protein in the serial assessment of disease activity in rheumatoid arthritis. Scand. J. Rheumatol.13, 39–44 (1984).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Sterling-Winthrop Research Institute, 12144, Rensselaer, New York, USA

    K. M. Connolly, E. Danis, D. J. Pruden & T. LaBrie

  2. Winthrop Pharmaceuticals, 90 Park Ave., 10016, New York, New York, USA

    V. J. Stecher

Authors
  1. K. M. Connolly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. J. Stecher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Danis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. J. Pruden
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. LaBrie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Connolly, K.M., Stecher, V.J., Danis, E. et al. Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs. Agents and Actions 25, 94–105 (1988). https://doi.org/10.1007/BF01969100

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01969100

Keywords

Search

Navigation